See more : 91App, Inc. (6741.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Jaguar Health, Inc. (JAGX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Jaguar Health, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Public Joint Stock Company Rosneft Oil Company (RNFTF) Income Statement Analysis – Financial Results
- Alexion Pharmaceuticals, Inc. (0QZM.L) Income Statement Analysis – Financial Results
- H-Farm S.p.A. (FARM.MI) Income Statement Analysis – Financial Results
- Nahar Spinning Mills Limited (NAHARSPING.NS) Income Statement Analysis – Financial Results
- ATMA Participações S.A. (ATMP3.SA) Income Statement Analysis – Financial Results
Jaguar Health, Inc. (JAGX)
About Jaguar Health, Inc.
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.76M | 11.96M | 4.34M | 9.39M | 5.78M | 4.42M | 4.36M | 141.52K | 258.38K | 0.00 |
| Cost of Revenue | 2.04M | 2.02M | 2.33M | 3.28M | 3.82M | 2.77M | 880.41K | 51.97K | 123.46K | 0.00 |
| Gross Profit | 7.72M | 9.94M | 2.00M | 6.11M | 1.96M | 1.65M | 3.48M | 89.56K | 134.92K | 0.00 |
| Gross Profit Ratio | 79.13% | 83.11% | 46.18% | 65.05% | 33.93% | 37.37% | 79.81% | 63.28% | 52.22% | 0.00% |
| Research & Development | 18.60M | 17.65M | 15.08M | 6.41M | 5.82M | 5.15M | 4.27M | 7.21M | 6.48M | 4.22M |
| General & Administrative | 16.59M | 17.87M | 17.10M | 14.39M | 13.50M | 12.28M | 11.25M | 5.98M | 5.34M | 0.00 |
| Selling & Marketing | 6.46M | 8.84M | 8.89M | 6.61M | 6.94M | 9.83M | 3.08M | 485.44K | 765.09K | 0.00 |
| SG&A | 23.05M | 26.71M | 26.00M | 21.00M | 20.44M | 22.11M | 14.33M | 6.47M | 6.10M | 4.10M |
| Other Expenses | 371.00K | 950.00K | -765.00K | 190.00K | 648.80K | 315.69K | 88.55K | -11.05K | -27.28K | 0.00 |
| Operating Expenses | 42.02M | 44.35M | 41.08M | 27.41M | 26.91M | 27.26M | 18.60M | 13.68M | 12.58M | 8.32M |
| Cost & Expenses | 44.05M | 46.37M | 43.41M | 30.69M | 30.72M | 30.03M | 19.48M | 13.73M | 12.70M | 8.32M |
| Interest Income | 0.00 | 12.72M | 8.42M | 2.79M | 5.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 6.38M | 12.72M | 8.42M | 2.79M | 5.73M | 2.63M | 1.21M | 985.55K | 3.32M | 0.00 |
| Depreciation & Amortization | 1.16M | 2.29M | 1.83M | 2.28M | 1.93M | 1.75M | 584.34K | 47.49K | 5.16K | -51.42K |
| EBITDA | -33.13M | -33.38M | -42.35M | -28.74M | -30.87M | -27.77M | -11.13M | -13.70M | -12.97M | -8.37M |
| EBITDA Ratio | -339.42% | -260.73% | -914.88% | -257.61% | -397.20% | -454.56% | 100.27% | -9,459.45% | -4,620.54% | 0.00% |
| Operating Income | -34.29M | -34.42M | -39.07M | -21.30M | -24.95M | -30.82M | -34.25M | -13.59M | -12.45M | -8.32M |
| Operating Income Ratio | -351.31% | -287.85% | -901.36% | -227.00% | -431.98% | -697.98% | -785.27% | -9,599.84% | -4,816.67% | 0.00% |
| Total Other Income/Expenses | -7.61M | -13.98M | -11.89M | -7.16M | -9.58M | -1.32M | -902.80K | -1.15M | -3.85M | -293.91K |
| Income Before Tax | -41.90M | -48.40M | -52.60M | -33.81M | -38.53M | -32.15M | -35.15M | -14.73M | -16.29M | -8.61M |
| Income Before Tax Ratio | -429.27% | -404.78% | -1,213.38% | -360.25% | -667.15% | -727.92% | -805.97% | -10,410.87% | -6,305.24% | 0.00% |
| Income Tax Expense | 0.00 | -941.00K | 7.65M | 2.98M | 10.00K | -1.28M | -13.18M | 1.14M | 3.82M | 345.34K |
| Net Income | -41.30M | -47.45M | -60.25M | -36.79M | -38.54M | -32.15M | -21.97M | -14.73M | -16.29M | -8.61M |
| Net Income Ratio | -423.11% | -396.91% | -1,389.87% | -392.02% | -667.32% | -727.92% | -503.73% | -10,410.87% | -6,305.24% | 0.00% |
| EPS | -107.42 | -36.18 | -101.07 | -214.22 | -1.75K | -15.51K | -27.26K | -249.73K | -479.16K | -204.99K |
| EPS Diluted | -107.42 | -36.18 | -101.07 | -214.22 | -1.75K | -15.51K | -27.26K | -249.73K | -479.16K | -204.99K |
| Weighted Avg Shares Out | 384.47K | 1.31M | 596.15K | 171.75K | 22.07K | 2.07K | 806.00 | 59.00 | 34.00 | 42.00 |
| Weighted Avg Shares Out (Dil) | 384.47K | 1.31M | 596.15K | 171.75K | 22.07K | 2.07K | 806.00 | 59.00 | 34.00 | 42.00 |
Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
New patent issued for core rare disease target indication for crofelemer Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with...
Magdalena Biosciences, a Joint Venture between Jaguar Health and Filament Health, Receives Second Tranche of Funding from One Small Planet
Magdalena Biosciences, a joint venture recently formed by Jaguar Health and Filament Health Corp., is focused on developing novel, natural prescription medicines derived from plants for mental health indications SAN FRANCISCO, CA / ACCESSWIRE / October 30, 2023 / Jaguar...
Jaguar Health to Present November 1st at Emerging Growth Conference
Individual and institutional investors as well as advisors, analysts, and members of the financial media are invited to attend Jaguar's real-time interactive presentation SAN FRANCISCO, CA / ACCESSWIRE / October 26, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that...
Napo Pharmaceuticals, a Jaguar Health Family Company, Accepted to Present Results of Its Pivotal Phase 3 OnTarget Study for Preventive Treatment of Cancer Therapy-Related Diarrhea December 7th at the San Antonio Breast Cancer Symposium
Top line results of this pivotal trial expected before Thanksgiving More than 1 million cancer patients in the US receive chemotherapy or radiation each year, according to the CDC, and cancer patients with diarrhea are 40% more likely to discontinue...
Magdalena Biosciences Initiates Preclinical Study to Evaluate Plant Extracts to Treat Depression, Anxiety, ADHD and Other Mental Health Indications
Magdalena Biosciences, a joint venture recently formed by Jaguar Health and Filament Health Corp., is focused on developing novel, natural prescription medicines derived from plants for mental health indications Magdalena launches corporate website SAN FRANCISCO, CA / ACCESSWIRE / October...
Independent Study Conducted at Boston Children's Hospital, Harvard Medical School, Shows Potential Utility of Jaguar Health's Crofelemer for Treatment of MVID, a Rare Childhood Disease
MVID, for which there are no approved drug treatments, is a life-threatening and ultra-rare autosomal recessive disease that affects newborns and children, leading to intestinal failure, significant morbidity and even death from severe secretory diarrhea Crofelemer has been granted Orphan...
Napo Pharmaceuticals to Exhibit at the October 25-28 Annual Association of Nurses in AIDS Care (ANAC) Conference for Mytesi, the Company's FDA-Approved Prescription Drug
Mytesi® (crofelemer) is indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy Napo to host educational dinner for nurses about HIV-related diarrhea and Mytesi during conference SAN FRANCISCO, CA / ACCESSWIRE / October...
Jaguar Health to Present October 17 at the Lytham Partners Fall 2023 Investor Conference and October 18 at the BIO Investor Forum
Top line results expected in the coming weeks for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome...
Jaguar Animal Health Exhibiting at October 12-14 VCS Annual Conference for Canalevia-CA1, the Company's FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
Canalevia®-CA1 is the first and only treatment for CID in dogs to receive any type of approval from the FDA SAN FRANCISCO, CA / ACCESSWIRE / October 10, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") under its...
Jaguar Health to Present October 3 at LD Micro's Main Event Investor Conference, and on October 5 at the Global Capital Network Investor Conference
Top line results expected late October 2023 for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and...
Source: https://incomestatements.info
Category: Stock Reports